Harbour BioMed has partnered with Yantai Lannacheng Biotechnology to develop next-generation radionuclide drug conjugates (RDCs), targeting tumor antigens with reduced side effects on healthy tissues. RDCs offer advantages over traditional radiotherapy and antibody-drug conjugates, potentially overcoming tumor heterogeneity and drug resistance. Harbour BioMed’s antibody discovery platforms, including Harbour Mice and HCAb technology, generate fully human monoclonal antibodies with low immunogenicity and high specificity. These antibodies enhance targeted drug delivery, improving therapeutic efficacy while minimizing side effects. The collaboration aims to expand innovative treatment options for patients globally.

Read more at Nasdaq: Harbour BioMed Collaborates With Lannacheng To Advance Next-Generation Radionuclide Drug Conjugates